The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451
Open accessAbstract
PURPOSE: In extensive-disease small-cell lung cancer (ED-SCLC), response rates to first-line platinum-based chemotherapy are robust, but responses lack durability. CheckMate 451, a double-blind phase III trial, evaluated nivolumab plus ipilimumab and nivolumab monotherapy as maintenance therapy following first-line chemotherapy for ED-SCLC. METHODS: Patients with ED-SCLC, Eastern Cooperative Oncology Group performance status 0-1, and no progression after ≤ 4 cycles of first-line chemotherapy were randomly assigned (1:1:1) to nivolumab 1 mg/kg plus ipilimumab 3 mg/kg once every 3 weeks for 12 weeks followed by nivolumab 240 mg once every 2 weeks, nivolumab 240 mg once every 2 weeks, or placebo for ≤ 2 years or until progression or unacceptable toxicity. Primary end point was overall survival (OS) with nivolumab plus ipilimumab versus placebo. Secondary end points were hierarchically tested. RESULTS: Overall, 834 patients were randomly assigned. The minimum follow-up was 8.9 months. OS was not significantly prolonged with nivolumab plus ipilimumab versus placebo (hazard ratio [HR], 0.92; 95% CI, 0.75 to 1.12; P = .37; median, 9.2 v 9.6 months). The HR for OS with nivolumab versus placebo was 0.84 (95% CI, 0.69 to 1.02); the median OS for nivolumab was 10.4 months. Progression-free survival HRs versus placebo were 0.72 for nivolumab plus ipilimumab (95% CI, 0.60 to 0.87) and 0.67 for nivolumab (95% CI, 0.56 to 0.81). A trend toward OS benefit with nivolumab plus ipilimumab was observed in patients with tumor mutational burden ≥ 13 mutations per megabase. Rates of grade 3-4 treatment-related adverse events were nivolumab plus ipilimumab (52.2%), nivolumab (11.5%), and placebo (8.4%). CONCLUSION: Maintenance therapy with nivolumab plus ipilimumab did not prolong OS for patients with ED-SCLC who did not progress on first-line chemotherapy. There were no new safety signals.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534 · cited 1×
“0 (1-54) nivolumab doses in the nivolumab arm, and 5.”
BackgroundFirst-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer
Horn, L., Mansfield, A. S., Szczęsna, A., Havel, L., Krzakowski, M., Hochmair, M. J., Huemer, F., Losonczy, G., Johnson, M. L., Nishio, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809064 · Cited by 3,586
Self-citationNivolumab plus ipilimumab in lung cancer with a high tumor mutational burden
Hellmann, M. D., Ciuleanu, T.-E., Pluzanski, A., Lee, J. S., Otterson, G. A., Audigier-Valette, C., Minenza, E., Linardou, H., Burgers, S., Salman, P., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801946 · Cited by 3,063 · cited 1×
“0 (1-54) nivolumab doses in the nivolumab arm, and 5.”
BackgroundSelf-citationPaz-Ares, L., Dvorkin, M., Chen, Y., Reinmuth, N., Hotta, K., Trukhin, D., Statsenko, G., Hochmair, M. J., Özgüroğlu, M., Ji, J. H., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32222-6 · Cited by 2,298 · cited 1×
“0 (1-54) nivolumab doses in the nivolumab arm, and 5.”
BackgroundSelf-citationAmerican Joint Committee on Cancer (2010) · Springer eBooks · doi:10.1007/978-0-387-88441-7 · Cited by 1,328
Antonia, S. J., López-Martin, J. A., Bendell, J., Ott, P. A., Taylor, M., Eder, J. P., Jäger, D., Pietanza, M. C., Le, D. T., de Braud, F., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30098-5 · Cited by 1,244
Hellmann, M. D., Rizvi, N. A., Goldman, J. W., Gettinger, S. N., Borghaei, H., Brahmer, J. R., Ready, N. E., Gerber, D. E., Chow, L. Q., Juergens, R. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30624-6 · Cited by 962
Self-citationHellmann, M. D., Callahan, M. K., Awad, M. M., Calvo, E., Ascierto, P. A., Atmaca, A., Rizvi, N. A., Hirsch, F. R., Selvaggi, G., Szustakowski, J. D., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.04.001 · Cited by 893
Self-citationRudin, C. M., Awad, M. M., Navarro, A., Gottfried, M., Peters, S., Csőszi, T., Cheema, P. K., Rodriguez-Abreu, D., Wollner, M., Yang, J. C.-H., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00793 · Cited by 760
Self-citationKulangara, K., Zhang, N., Corigliano, E., Guerrero, L., Waldroup, S., Jaiswal, D., MS, M. J., Shah, S., Hanks, D., Wang, J., et al. (2019) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2018-0043-oa · Cited by 536
Combination Therapy with Anti–CTLA-4 and Anti–PD-1 Leads to Distinct Immunologic Changes In Vivo
Das, R., Verma, R., Sznol, M., Boddupalli, C. S., Gettinger, S. N., Kluger, H., Callahan, M., Wolchok, J. D., Halaban, R., Dhodapkar, M. V., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1401686 · Cited by 461
Dissecting the mechanisms of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0275-8 · Cited by 434
Chung, H. C., Piha-Paul, S. A., Lopez-Martin, J., Schellens, J. H. M., Kao, S., Miller, W. H., Delord, J.-P., Gao, B., Planchard, D., Gottfried, M., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.12.109 · Cited by 408
Brahmer, J. R., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30690-3 · Cited by 348
Self-citationThird-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032
Ready, N., Farago, A. F., de Braud, F., Atmaca, A., Hellmann, M. D., Schneider, J. G., Spigel, D. R., Moreno, V., Chau, I., Hann, C. L., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.10.003 · Cited by 344
Self-citationReady, N. E., Ott, P. A., Hellmann, M. D., Zugazagoitia, J., Hann, C. L., de Braud, F., Antonia, S. J., Ascierto, P. A., Moreno, V., Atmaca, A., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.10.004 · Cited by 315 · cited 1×
“…phase I or II CheckMate 032 trial, which suggested improved ef fi cacy with combination therapy (at varying doses) versus nivolumab alone in SCLC. 12,13 These dosages notably differ from those indicated in non – small-cell lung cancer 25-27 ; however, tumor-speci fi c factors may affect optimal…”
BackgroundSelf-citationSchiller, J. H., Adak, S., Cella, D., DeVore, R. F., & Johnson, D. H. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.8.2114 · Cited by 294
Current standards for clinical management of small cell lung cancer
Farago, A. F., & Keane, F. K. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.01.16 · Cited by 265
Kim, H. R., Ha, S.-J., Hong, M. H., Heo, S. J., Koh, Y. W., Choi, E. C., Kim, E. K., Pyo, K. H., Jung, I., Seo, D., et al. (2016) · Scientific Reports · doi:10.1038/srep36956 · Cited by 256
Self-citationGadgeel, S. M., Pennell, N. A., Fidler, M. J., Halmos, B., Bonomi, P., Stevenson, J., Schneider, B., Sukari, A., Ventimiglia, J., Chen, W., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.05.002 · Cited by 212
Sun, J., Zhou, W., Choi, Y., Choi, S., Kim, S. E., Wang, Z., Dolled-Filhart, M. P., Emancipator, K., Wu, D., WEINER, R. S., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.04.007 · Cited by 153
Self-citationReady, N., Pang, H., Gu, L., Otterson, G. A., Thomas, S. P., Miller, A. A., Baggstrom, M. Q., Masters, G. A., Graziano, S. L., Crawford, J., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.3105 · Cited by 141
Self-citationNew Advances in the Second-Line Treatment of Small Cell Lung Cancer
Hurwitz, J. L., McCoy, F. P. G., Scullin, P., & Fennell, D. A. (2009) · The Oncologist · doi:10.1634/theoncologist.2009-0026 · Cited by 119
Yu, H., Chen, Z., Ballman, K. V., Watson, M. A., Govindan, R., Lanc, I., Beer, D. G., Bueno, R., Chirieac, L. R., Chui, M. H., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.09.006 · Cited by 92
Self-citationRamalingam, S. S., Dahlberg, S. E., Belani, C. P., Saltzman, J. N., Pennell, N. A., Nambudiri, G. S., McCann, J., Winegarden, J. D., Kassem, M. A., Mohamed, M. K., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.01006 · Cited by 74
Rossi, A., Garassino, M. C., Cinquini, M., Sburlati, P., Maïo, M. D., Farina, G., Gridelli, C., & Torri, V. (2010) · Lung Cancer · doi:10.1016/j.lungcan.2010.02.001 · Cited by 73
Ito, S., Okano, S., Morita, M., Saeki, H., Tsutsumi, S., Tsukihara, H., Nakashima, Y., Ando, K., Imamura, Y., Ohgaki, K., et al. (2016) · Annals of Surgical Oncology · doi:10.1245/s10434-016-5376-z · Cited by 62
Cited by
Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends
Sun, Q., Hong, Z., Zhang, C., Wang, L., Han, Z., & Ma, D. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01522-4 · Cited by 598
Megyesfalvi, Z., Gay, C. M., Popper, H., Pirker, R., Ostoros, G., Heeke, S., Lang, C., Hoetzenecker, K., Schwendenwein, A., Boettiger, K., et al. (2023) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21785 · Cited by 369
Metadata
- Authors
- Owonikoko, T. K., Park, K., Govindan, R., Ready, N., Reck, M., Peters, S., Dakhil, S. R., Navarro, A., Rodríguez-Cid, J., Schenker, M., Lee, J.-S., Gutierrez, V., Percent, I., Morgensztern, D., Barrios, C. H., Greillier, L., Baka, S., Patel, M., Lin, W. H., Selvaggi, G., Baudelet, C., Baden, J., Pandya, D., Doshi, P., & Kim, H. R.
- Venue
- Journal of Clinical Oncology
- Published
- 2021-04-20
- Volume
- 39
- Issue
- 12
- Pages
- 1349-1359
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W3133896744
- Cited by
- 274
- References
- 27
- FWCI
- 16.31
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.